ALZpath, Siemens Healthineers Partner on Blood-Based Alzheimer’s Testing
Licensing agreement will integrate ALZpath's pTau217 antibody into Siemens' Atellica analyzer test menu for IVD Alzheimer's diagnostics.
Licensing agreement will integrate ALZpath's pTau217 antibody into Siemens' Atellica analyzer test menu for IVD Alzheimer's diagnostics.
The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
UCLA Health researchers find cell-free DNA combined with machine learning can distinguish ALS from other neurological conditions.
The Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.
The Liaison Plex Gastrointestinal Flex Assay detects 24 targets and offers broad parasite coverage with pay-per-target flexibility.
The molecular diagnostic system can identify complicated UTI pathogens and antibiotic resistance markers at the point-of-care in approximately 15 minutes.
The gene expression test is designed to identify patients more likely to respond to JAK inhibitors versus Th2-targeted therapies.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
The financing will accelerate clinical validation and commercial readiness of brain-derived blood biomarkers based on circular RNA technology.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The rapid diagnostic test achieved 100% sensitivity and negative predictive value in a 107-patient evaluation at Bordeaux University Hospital.